Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
VIENNA, Austria and KING OF PRUSSIA, Pa., April 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious …